| Property | Value |
|---|---|
| Protein Name | Caspase-1 |
| Gene | CASP1 |
| UniProt ID | P29466 |
| Molecular Weight | ~45 kDa (active enzyme) |
| Subcellular Localization | Cytoplasm, inflammasome complexes |
| Protein Family | Caspase family (inflammatory caspases) |
| Tissue Expression | Primarily immune cells; low in healthy brain |
Caspase-1 is an inflammatory caspase encoded by the CASP1 gene that plays central roles in the innate immune response and inflammatory cell death (pyroptosis)[1]. It is synthesized as an inactive zymogen (pro-caspase-1) that is activated by assembly into inflammasome complexes in response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs).
Once activated, caspase-1 performs two critical functions: (1) cleaving pro-interleukin-1β (pro-IL-1β) and pro-IL-18 to produce active pro-inflammatory cytokines, and (2) cleaving gasdermin D to initiate pyroptotic cell death. In the brain, caspase-1 activation in microglia and neurons contributes to neuroinflammation and neuronal loss in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[2].
Caspase-1 contains several structural features[1:1]:
Caspase-1 is activated through a multi-step process:
Several inflammasomes activate caspase-1:
| Inflammasome | Sensor | Activator |
|---|---|---|
| NLRP3 | NLRP3 | ATP, crystals, aggregates |
| AIM2 | AIM2 | Double-stranded DNA |
| NLRC4 | NLRC4 | Bacterial flagellin |
| NLRP1 | NLRP1 | Toxins, viral proteins |
Caspase-1 processes key inflammatory cytokines:
Caspase-1 triggers pyroptotic cell death[2:1]:
In the immune system, caspase-1 functions in:
Caspase-1 is a key player in AD neuroinflammation[3]:
Inflammasome Activation:
Pathogenic Mechanisms:
Therapeutic Targeting:
Caspase-1 contributes to PD through:
| Disease | Caspase-1 Role |
|---|---|
| ALS | Motor neuron pyroptosis |
| MS | Oligodendrocyte death |
| Huntington's | Mutant huntingtin activates NLRP3 |
Caspase-1 drives neuroinflammation through:
Targeting caspase-1 is actively being explored[2:2]:
| Strategy | Approach | Status |
|---|---|---|
| Caspase-1 inhibitors | Small molecules (VX-765, YVAD) | Clinical trials |
| NLRP3 inhibitors | MCC950, Dapansutrile | Clinical trials |
| IL-1R antagonists | Anakinra, Canakinumab | Various stages |
| Anti-inflammatory | Minocycline, Edaravone | Approved/useful |
Martin F, et al. Caspase-1 in neurodegeneration. Nature Reviews Neuroscience. 2019. ↩︎ ↩︎
Browning KL, et al. Inflammasome activation in neurodegenerative disease. Cell. 2022. ↩︎ ↩︎ ↩︎
Schwartz J, et al. Pyroptosis and the innate immune response in AD. Acta Neuropathologica. 2023. ↩︎